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Abstract
Background: Many patients with ischemic heart disease have cardiovascular risk factors such as cigarette smoking. We
tested the effect of nicotine (a key component of cigarette smoking) on the therapeutic effects of human embryonic stem
cell-derived endothelial cells (hESC-ECs).
Methods and Results: To induce endothelial cell differentiation, undifferentiated hESCs (H9 line) underwent 4-day floating EB
formation and 8-day outgrowth differentiation in EGM-2 media. After 12 days, CD31
+ cells (13.762.5%) were sorted by
FACScan and maintained in EGM-2 media for further differentiation. After isolation, these hESC-ECs expressed endothelial
specific markers such as vWF (96.361.4%), CD31 (97.262.5%), and VE-cadherin (93.762.8%), form vascular-like channels, and
incorporated DiI-labeled acetylated low-density lipoprotein (DiI-Ac-LDL). Afterward, 5610
6 hESC-ECs treated for 24 hours with
nicotine(10
28 M) or PBS(ascontrol)were injected into the heartsof mice undergoing LAD ligationfollowed byadministration
for two weeks of vehicle or nicotine (100 mg/ml) in the drinking water. Surprisingly, bioluminescence imaging (BLI) showed
significant improvement in the survival of transplanted hESC-ECs in the nicotine treated group at 6 weeks. Postmortem
analysis confirmed increased presence of small capillaries in the infarcted zones. Finally, in vitro mechanistic analysis suggests
activation of the MAPK and Akt pathways following activation of nicotinic acetylcholine receptors (nAChRs).
Conclusions: This study shows for the first time that short-term systemic administrations of low dose nicotine can improve
the survival of transplanted hESC-ECs, and enhance their angiogenic effects in vivo. Furthermore, activation of nAChRs has
anti-apoptotic, angiogenic, and proliferative effects through MAPK and Akt signaling pathways.
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Introduction
Since the first description of the isolation and expansion of
human embryonic stem cells (hESCs) in 1998[1,2], there has been
tremendous excitement over the potential clinical and therapeutic
applications of hESC derivatives[3,4]. Derivatives of hESCs offer
potential effective treatments for intractable diseases such as heart
failure, neurological injury, and diabetes. Accordingly, numerous
protocols have been developed for the differentiation of endothe-
lial cells[5,6,7,8,9] [14–16], cardiomyocytes[10], neurons[11], and
pancreatic islet cells[12], among other cell types.
In particular, hESC-derived endothelial cells (hESC-ECs) are a
promising cell source for the treatment of a variety of ischemic
diseases, including stroke, myocardial ischemia, and peripheral
vascular disease[6,13,14]. However, many significant hurdles must
be overcome before hESC-EC regeneration can become clinically
relevant, including massive cell death and apoptosis following
transplantation[15], teratoma formation[16], and immune rejec-
tion[17] by the host organism.
Cardiovascular (CV) risk factors, including cigarette smoke, are
known to reduce the number and function of adult endothelial
progenitor cells (EPCs) in humans[18]. We are interested in
understanding how one such known major CV risk factor, cigarette
smoke, would affect the function of hESC-ECs. Thus, this study
focused on the effects of nicotine, the primary addictive component
among 4000 known constituents of tobacco smoke, on hESC-ECs.
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Preparation of hESC-Ecs
Karyotypically normal hESCs (H9 line from Wicell, passages
35–45) were maintained in the undifferentiated state on an
inactivated mouse embryonic fibroblast (MEF) feeder layer as
previously described[19]. The medium consisted of Dulbecco’s
modified Eagle’s medium (DMEM)/F-12 (Invitrogen, CA), 20%
knockout serum replacement (Invitrogen, CA), 0.1 mM nonessen-
tial amino acids (Invitrogen, CA), 2 mM L-glutamine (Invitrogen,
CA), 0.1 mM b-mercaptoethanol (Sigma, MO), and 8 ng/ml
basic fibroblast growth factor (bFGF, Invitrogen, CA). Prior to
endothelial differentiation, hESCs were seeded onto Growth
Factor Reduced (GFR) Matrigel-coated plates (BD Biosciences,
CA) in mTeSR medium (StemCell Technologies Inc., Vancouver,
Canada) for MEF deprivation. To initiate hESC differentiation
into human embryoid bodies (EBs), the undifferentiated hESCs
were transferred to ultra-low attachment plates (Corning Incor-
porated, Corning, NY) for 4 days and cultured in differentiation
medium containing Iscove’s modified Dulbecco’s medium
(IMDM) (Invitrogen, CA), 20% defined fetal bovine serum (FBS)
(Hyclone, UT), 0.1 mM nonessential amino acids, 2 mM L-
glutamine, 450 mM monothioglycerol (Sigma), 50 U/ml penicillin
(Sigma), and 50 mg/ml streptomycin (Sigma). After 4 days, hEBs
were transferred to a 0.1% gelatin coated dish and grown for an
additional 8 days in endothelial cell growth medium-2 (EGM-2,
Clonetics Corp., CA) that contains 2% FBS, 0.04% hydrocorti-
sone, 0.1% heparin, 0.1% human epidermal growth factor
(hEGF), 0.1% long R3-human insulin-like growth factor (IGF-1),
0.1% ascorbic acid, 0.4% human fibroblast growth factor (hFGF)-
B, 0.1% vascular endothelial growth factor (VEGF), 0.05%
gentamicin, and 0.05% amphotericin-B.
Flow cytometry cell sorting of hESC-Ecs
After 12 days of differentiation, flow cytometry sorting was used
to purify hESC-ECs. Single cell suspensions were obtained by
treating cell cultures with PBS-based cell dissociation buffer
(Invitrogen, CA) at 37uC for 30 min. Cells were then passed
through a 40-mm cell strainer (BD Falcon, San Diego) and
incubated for 30 min at 4uC with mouse phycoerythrin (PE)-
conjugated anti-human CD31 (BD Bioseciences). CD31
+ cells
were isolated using FACScan (Becton Dickinson). Selection for
PE-conjugated CD31
+ endothelial cells was carried out by first
gating on larger cells within a SSC-A and FSC-A dot plot to
exclude non-viable cells and debris. The CD31
+ cell population
was then identified by PE
+ expression compared to unstained
control cells. To expand the isolated hESC-ECs, CD31
+ cells were
grown on 0.1% gelatin-coated plates in EGM-2, changing the
medium every 2 days. After passage 3, we again performed flow
cytometry sorting with CD31 antibody to further purify hESC-
ECs for subsequent cultures. In order to study the phenotype of
CD31
+ cells thus obtained, we confirmed the endothelial
phenotype of our CD31
+ twice-purified hESC-ECs by flow
cytometry analysis for the expression of vWF, CD31, and VE-
cadherin (BD Biosciences), DiI-ac-LDL uptake assay, and Matrigel
tube formation assay as previously described [15].
pUb-Fluc-eGFP transduction of hESCs
To track transplanted cells in vivo, we used an H9 hESC line that
stably expresses a double fusion (DF) reporter gene containing
firefly luciferase (Fluc) and enhanced green fluorescence protein
(eGFP)[15]. After fixing with 4% paraformaldehyde in PBS for 15
minutes and incubating with 4% normal goat serum for 30
minutes to block nonspecific binding, immunostaining was
performed with Oct-4 antibody (Santa Cruz Inc., CA) on both
non-transduced control hESCs and
DF+hESCs to test the effect of
reporter gene expression on hESC phenotype. Cells were then
incubated with Alexa 594-conjugated rabbit anti-goat secondary
antibodies (Invitrogen, CA) for 30 minutes and nuclear counter-
stained with 4, 6-diamidino-2- phenylindole (DAPI). Images were
obtained with a Zeiss Axiovert microscope (Sutter Instrument Co.,
USA). To test the effect of transduced reporter gene on cellular
proliferation, as well as the effect of nAChRs activation on
reporter gene expression, control (non-transduced) hESC-ECs and
stably transduced
DF+hESC-ECs were plated uniformly in 96-well
plates at a density of 5,000 cells per well, in the presence of
different nicotine concentrations (10
28,1 0
26,1 0
24,o r1 0
22 M) at
24, 48, and 72 hour time points, respectively. At each indicated
time point, MTS/PMS solution (Promega) was added to each well
for 3 hours. The optical density (O.D.) of each well was measured
on an ELISA micro-plate reader at 490 nm, according to a
previously published protocol[20]. Ten samples per group were
assayed and averaged. Experiments were performed in triplicate.
Cardiac transplantation of
DF+hESC-Ecs
Eight-week-old female SCID Beige mice (23–27 g, Charles
River Laboratories, Inc.) were stratified to one of four groups that
underwent aseptic lateral thoracotomy and ligation of the left
anterior descending (LAD) coronary artery as described[21].
Group 1 animals (n=5) received intramyocardial injections of
5610
6D F +hESC-ECs in 30 ul of 10
28 M nicotine solution; cells
had been pretreated overnight with 10
28 M nicotine. Postoper-
atively, animals received daily administrations of nicotine in the
drinking water (which was a 2% saccharine solution, with nicotine
in a concentration of 100 ug/ml, administered per libitum)[22].
Group 2 animals (n=5) received intramyocardial injections of
non-pretreated
DF+hESC-ECs suspended in 30 ul PBS, as well as
2% saccharine in their drinking water post-surgery but no nicotine
treatment. Group 3 animals (n=5) did not receive cell injections
but rather intramyocardial injections with 30 ul of 10
28 M
nicotine solution, as well as oral administrations of nicotine in
the drinking water as described above (negative control for group
1). Group 4 animals (n=5) received intramyocardial injections
with 30 ul of phosphate buffered saline (PBS) and 2% saccharine
in drinking water after surgery (negative control for group 2).
Harvested
DF+hESC-ECs were kept on ice for ,30 min for
optimal viability. Serum nicotine levels were measured as
previously described[22]. Animals that recovered uneventfully
underwent bioluminescence imaging (BLI) later. Study protocols
were approved by the Stanford Animal Research Committee.
Optical BLI of transplanted
DF+hESC-Ecs
At specific timepoints, BLI was performed using the Xenogen In
Vivo Imaging System (IVIS 200, Xenogen, Alameda, CA).
Animals received isoflurane (2%) for general anesthesia. After
intraperitoneal injection of the reporter probe D-luciferin
(375 mg/kg body weight), animals were imaged for 30 minutes
with 1-minute acquisition intervals. The same mice were scanned
for 6 weeks. BLI images were analyzed using the Igor image
analysis software (Wavemetrics, Lake Oswego, OR). Regions of
interest (ROIs) were drawn over the signals, and BLI was
quantified in units of maximum photons per second per centimeter
square per steradian (p/s/cm
2/sr) as described [16].
Postmortem histology
Animals were sacrificed for postmortem histology study at week
6. The hearts were embedded in Optical Cutting Temperature
(OCT) compound (Tissue-Tek Sakura Finetek, CA) and snap
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proximal and apical regions of the infarct zone. To trace the
transplanted
DFhESC-ECs in the ischemic heart, slides were
double stained for GFP (Molecular Probes) and human-specific
CD31 (BD Pharmingen). Sections were counterstained with DAPI.
Cell engraftment was confirmed by identification of GFP and
human-specific CD31 expression under fluorescent microscopy.
To detect mouse microvascular density (MVD) in the peri-infarct
area, immunohistochemical staining for mouse-specific CD31 was
carried out by using the Biocare Medical Universal HRP-DAB kit
(Biocare Medical, Walnut Creek, CA) as described[23]. The
staining was performed and number of capillary vessels was
counted in 10 randomly selected areas using a light microscope
(x200 magnification).
Capillary-like tube formation and cell apoptosis study in
vitro
In order to further study the dose-dependent effect of nicotine
on hESC-EC angiogenesis under hypoxic conditions, 24-well
plates were coated with growth factor reduced (GFR) Matrigel and
equilibrated with growth factor and serum-deprived EBM-2
medium[24]. Cells (1610
5) were seeded into each well containing
different concentrations of nicotine (10
28,1 0
26,1 0
24,o r1 0
22 M)
followed by incubation in conditions of normoxia (5% CO2, 21%
O2, and 74% N2) or hypoxia (5% CO2,1 %O 2, and 94% N2).
Development of tube formation was assessed after 48 hours using
an inverted phase-contrast microscope (Zeiss AxioVert 100 M;
Carl Zeiss Inc.). Images were captured with a video graphic system
(Zeiss AxioCam; Carl Zeiss Inc.). Relative tube-like formation was
determined by measuring the length of tube-like structures in five
random fields from each well and expressed as percent of vehicle-
treated cells [25]. To determine whether nicotine can improve the
survival of hESC-ECs by reducing cellular apoptosis during
hypoxia, hESC-ECs were cultured for 24 and 48 hours in growth
factor and serum-deprived EBM-2 medium, at 37uC under
hypoxic conditions (5% CO2,1 %O 2, and 94% N2). The
proportion of apoptotic hESC-ECs in comparison to the total
hESC-ECs was determined by staining with PE-conjugated
Annexin-V (Sigma, MO), and the number of dead cells was
determined by staining with 7-AAD, as previously described [26].
Stained cells were analyzed by flow cytometry (BD LSR cell
analyzer, San Jose, CA).
Immunoblotting
hESC-ECs were incubated with or without nicotine in
normoxia (5% CO2, 21% O2, and 74% N2) or hypoxia (5%
CO2,1 %O 2, and 94% N2) for 48 h. Samples (n=3) were then
rinsed in chilled PBS before lysing with RIPA buffer (Pierce)
containing protease inhibitors. Proteins were quantified by BCA
protein assay kit (Pierce) for equal loading. Sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) was carried out
using NuPage 4–12% Bis-Tris pre-cast gels (Invitrogen), and the
samples were then transferred onto nitrocellulose membranes. The
membranes were blocked in 5% BSA before incubating with the
following monoclonal antibodies: HIF-1a (Novus Biologicals),
pAkt1 (Cell Signaling Technology), Akt1 (Cell Signaling Technol-
ogy), pMAPK (Cell Signaling Technology), MAPK (Cell Signaling
Technology), or total actin (Sigma). Horse radish peroxidase
(HRP)-conjugated anti-rabbit (GE) secondary antibody was
applied, and the proteins were visualized by an ECL Detection
Kit (Amersham). Protein quantities for pMAPK and pAkt1 were
normalized to total MAPK and Akt1, respectively. HIF quantities
were normalized by total actin abundance. Data was quantified
using Image J software (NIH, Bethesda, MD).
RNA isolation, reverse transcription, and quantitative
polymerase chain reaction
Total RNA isolation was carried out with the RNEasy Kit
(Qiagen) with modifications. Samples were lysed in Trizol
(Invitrogen) before adding 200 ml chloroform per ml Trizol to
each sample and then centrifuging for phase separation. The
aqueous phase containing RNA was removed and combined with
3.5x the volume of RLT lysis buffer and 2.5x ethanol. The
mixture was then applied to an RNeasy mini column, and purified
RNA was obtained following the manufacturer’s instructions.
First strand DNA was synthesized by Superscript II reverse
transcriptase (Invitrogen) according to the manufacturer’s in-
struction. Taqman real-time PCR assays for VEGF-A, bFGF, and
nAChRs a1, a5, a7, and a9 were purchased from Applied
Biosystems. Oligonucleotides for 18S were generated based on
sequences from Shetzline et al.[27]. Real-time PCR reactions were
performed on a 7300 Real-Time PCR system (Applied Biosys-
tems) for 40 cycles. The data were assessed by the DDCt
method[28], normalized to 18S housekeeping gene, and
expressed as relative fold changes.
Bromodeoxyuridine (BrdU) Incorporation
To examine the effect of nicotine on cell proliferation in 1% O2
conditions, hESC-ECs were cultured in the presence of EBM
containing 10
28 M nicotine for up to 2 days. At the indicated
time points, the samples were pulsed by BrdU for 2 hours and
then fixed in ethanol (n=3). The samples were then immuno-
fluorescently stained for BrdU expression using a fluorescein-
conjugated detection kit according to the manufacturer’s
instructions (Roche Applied Sciences, Indianapolis, IN). Hoechst
33342 nuclear dye was then applied to visualize total nuclei.
Images were acquired with 20X objectives, and the percentage of
BrdU-expressing cells was quantified out of at least 300 cells using
Image J software.
Akt Inhibition Assay
To verify the role of Akt in modulating nicotine’s enhacement in
cell survival under hypoxic conditions, hESC-ECs were cultured in
EBM in 1% O2 hypoxia in the presence or absence of 10
28 M
nicotine. After 24 h, the cells were treated with 5 mM Akt IV
inhibitor (Calbiochem), 10
28 M Nicotine, or 5 mM Akt IV
inhibitor +10
28 M Nicotine for 1 h in hypoxia (n=4). Cells were
assessed for viability using the Live/Dead cytotoxicity assay
(Invitrogen) in which live cells could incorporate calcein-AM
(green), whereas dead cells were labeled by ethidium homodimer
(red). Samples were then imaged by fluorescence microscopy with
10X objectives.
Statistical analysis
All results are expressed as mean 6 standard deviation, except
where defined elsewise. Statistical significance was tested was
performed by the Student’s t-test for comparison of 2 groups or
one-way analysis of variance (ANOVA) with Holm’s adjustment
for multiple comparisons. Statistical significance was accepted at
P,0.05.
Results
Differentiation and characterization of hESC-Ecs
To enhance the yield of endothelial cells from hESCs, a newly
developed protocol was used to induce the differentiation of
hESC-ECs by sequential treatment over 4 days with floating EB
formation and 8 days of outgrowth differentiation from EBs in
Nicotine’s Effect on hESC-ECs
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improve endothelial cell proliferation (Figure 1A). Compared
with our previous hEB spontaneous differentiation method,
which used 12-day floating hEB formation to induce differenti-
ation (typically yielding ,3% endothelial cells[15]), the floating/
outgrowth hEB protocol consistently yielded .10% endothelial
cells. After flow cytometry purification, cultures of highly pure
vWF (96.361.4%), VE-cadherin (93.762.8%), and CD31
(97.262.5%) triple positive cell populations were readily obtained
(Figure 1B). After further expansioni nE G M - 2m e d i u m ,t h e s e
hESC-ECs were characterized for endothelial phenotype (i.e.,
ability to form tube-like structures in Matrigel and to incorporate
DiI-ac-LDL), and for endothelial gene expression. After 12–
24 hour incubation periods on Matrigel coated plates, we
observed tube-like structures that were similar in morphology to
human umbilical endothelial cells (HUVECs) (Figure 2A). In
addition, DiI-ac-LDL uptake, which has been used to character-
ize endothelial cells [29], was avidly taken up by hESC-ECs
(Figure 2B). In contrast, undifferentiated hESCs showed no
uptake of DiI-ac-LDL. Quantitative real-time PCR expression of
nAChRs in hESC-ECs and HMVDECs, expressed as relative
fold changes with respect to hESCs, showed comparable gene
expression levels for nAChR a1 (20.6614.2 vs 14.260.1), a5
(0.860.2 vs 0.660.1), a7( 0 . 6 60.1 vs 0.560.1), and a9( 1 . 0 60.1
vs 3.062.2 (P=NS)(Figure 2C). Thus, these assays demonstrate
that the purified hESC-ECs resemble mature endothelial cells
and express nAChRs. Interestingly, when compared to hESCs,
the hESC-ECs and HMVDECs showed significantly lower
relative gene expression levels for nAChRs a5, a7a n da9
(Figure 2C).
Characterization of hESCs stably transduced with
reporter genes for molecular imaging
In order to non-invasively track the effect of nicotine on hESC-
EC survival and localization in vivo, hESCs were transduced with a
double fusion (DF) reporter gene consisting of Fluc and eGFP
(Figure 3A). Both the non-transduced hESCs and stably
transduced
DF+hESCs showed similar expression patterns of stem
cell markers Oct-4, whereas only transduced
DF+hESCs expressed
eGFP as expected (Figure 3B).
DF+hESCs also showed similar
proliferation and viability as non-transduced hESCs, suggesting no
significant adverse effects by reporter gene expression (Figure 3C–
D). We also observed a strong correlation (r
2=0.98) between Fluc
activity and
DF+hESC-EC numbers (Figure 3E). In order to assess
Figure 1. Differentiation of hESCs to an endothelial lineage. (A) hESCs were allowed to form embryoid bodies (EB) for 4 days in
differentiation medium and ultra-low attachment dishes. EBs were then transferred to 0.1% gelatin coated dishes and grown in EGM-2 media for
another 8 days. On day 13, greater than 12% of cells expressed CD31. (B) After 6 days of culture, CD31
+ hESC-ECs expressed high levels of CD31, VE-
cadherin, and vWF. Scale bar, 20 mm.
doi:10.1371/journal.pone.0007040.g001
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reporter Fluc activity, 1610
4 control hESC-ECs and 1610
4
transduced hESC-ECs were cultured with or without the presence
of various concentrations of nicotine (10
22,1 0
24,1 0
26,1 0
28 M)
for 24–72 hours (Figure 3F–H). BLI of Fluc activity as a measure
of cell numbers suggested that pharmacological doses of nicotine
(10
22–10
24 M nicotine) led to significant cell death within 24–
72 hours, but interestingly clinically relevant concentrations of
nicotine (10
28–10
26 M) enhanced cell survival at 72 hours
(P,0.01). The enhancement of Fluc activity by clinically relevant
concentrations of nicotine was further confirmed by MTS assay,
suggesting that 10
28–10
26 M nicotine could enhance cell
proliferation.
nAChRs activation promotes survival of
DF+hESC-EC in
ischemic myocardium
To understand how nicotine might affect the survival and
function of cardiac delivered hESC-ECs, animals received
Figure 2. In vitro functional assessment and nAChR expression of hESC-ECs. (A) hESC-ECs formed visible tube-like structures beginning at
12 hours of culture on Matrigel. These structures were similar in morphology to human umbilical endothelial cells (HUVECs) used as positive control
in this experiment (n=8). (B) In contrast to undifferentiated hESCs, hESC-ECs were able to incorporate DiI-ac-LDL, a characteristic of mature
endothelial cells. (C) Like human dermal microvascular endothelial cells (HMVDECs), hESC-ECs express similar levels of a1, a5, a7 and a9 nAChRs
(n=3). Scale bar, 20 mm.
doi:10.1371/journal.pone.0007040.g002
Figure 3. Stable lentiviral transduction of hESCs with double fusion (DF) reporter gene. (A) Schema of the DF reporter gene containing
Fluc and eGFP. (B) Immunostaining of
DF+hESCs and control hESCs demonstrates similar expression of the stem cell marker Oct-4, while only
DF+hESCs express eGFP.
DF+hESC-ECs and non-transduced hESC-ECs had similar (C) cell proliferation and (D) cell viability rates over 72 hours,
indicating that the Fluc reporter gene did not affect hESC characteristics. (E) A robust correlation exists between cell number and Fluc activity
(R
2=0.98). (F) 1610
4 hESC-ECs were cultured in the presence or absence of nicotine at 5 different concentrations (10
22,1 0
24,1 0
26,1 0
28 Mo r
control PBS over 3 days. (G) Quantification of BLI signal indicated that 10
26–10
28 M nicotine concentrations caused a significant enhancement in cell
proliferation compared with other concentrations and PBS control group at day 3 (n=8, *P,0.05, ***P,0.001). (H) Likewise, cell numbers were
confirmed with serial spectrophotometer- based optical density (OD) which showed similar results. Scale bar, 20 mm.
doi:10.1371/journal.pone.0007040.g003
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6D F +hESC-ECs, and their diets
supplemented with nicotine at a dose of 100 mg/ml in drinking
water (Figure 4A). BLI was performed on days 1, 7, week 2, 4 and
6 after transplantation. Cell signal was most robust immediately
after transplantation and gradually decreased both in the nicotine-
treated (group 1) and vehicle groups (group 2) from day 2 to week
6( Figure 4B). The short course of nicotine administration
enhanced the long-term survival of implanted
DF+hESC-ECs. At
week 6, immunohistochemistry showed vessel-like structures
formed in part by
DF+hESC-ECs at the peri-infarct regions in
the nicotine-treated group. These cells can be identified by double
staining for CD31 (endothelial marker) and eGFP (reporter gene)
as shown in (Figure 4C). Animals receiving intramyocardial
injections of either 30 mlo f1 0
28 M nicotine (group 3) or 30 mlo f
PBS (group 4) but without hESC-ECs showed no BLI signals as
expected (data not shown). In addition to enhancing cell survival,
nAChR activation also promoted significantly higher levels of
angiogenesis. Mouse myocardial neovascularization as assessed by
microvessel density (MVD) was enhanced after receiving hESC-
EC transplantation plus short-term nicotine treatment at 6 weeks
after cell delivery (P,0.01), when compared to all other treatment
groups (Figure 5A–B).
Activation of nAChRs improve the angiogenic and anti-
apoptotic potential of hESC-ECs through MAPK/Akt/HIF-
1a pathway in vitro
We next assessed whether nicotine imparted angiogenic or pro-
survival cues to hESC-ECs in hypoxic environments. To test the
effect of nicotine on the angiogenic potential of hESC-EC in
hypoxia, we assayed for the formation of tube-like structures on
growth factor reduced Matrigel in the setting of hypoxia (5% CO2,
1% O2, 94% N2 culture conditions). Under hypoxic conditions for
48 hours, we observed a significant reduction in tube-like
structures when treated with pharmacological doses of nicotine
(10
22 Mo r1 0
24 M) (Figure 6A). In stark contrast, when we used
clinically relevant doses of nicotine, we observed a significant
increase in tube-like formation with a maximum response at
10
28 M nicotine (Figure 6B). To further elucidate the apparent
positive effect of 10
28 M nicotine on hESC-EC survival, we next
quantified the cellular apoptosis induced by hypoxia (1% O2).
Using Annexin-V and 7-AAD staining to assess cell apoptosis and
death, respectively, we found that 10
28 M nicotine significantly
attenuated the percentage of apoptotic hESC-ECs compared with
PBS: 4.761.4% vs. 11.362.1% after 24 hour hypoxia incubation
and 7.261.0% vs. 19.563.8% after 48-hour hypoxia incubation
Figure 4. Activation of nAChRs promotes hESC-EC survival in ischemic hearts. (A) Following LAD ligation,
DF+hESC-ECs were injected into
peri-infarct area in adult SCID mice. In the nicotine group, mice were given nicotine in their drinking water (100 ug/ml) for 2 weeks post-surgery. In
the vehicle group, mice were maintained without nicotine administration. Serial BLI was used to evaluate the survival of transplanted cells on days 1,
7, weeks 2, 4 and 6. (B) Quantification of the resulting imaging signals indicated significant enhancement of cell survival in nicotine-treated group
compared with vehicle group, starting from day 7 (*P,0.01). (C) Immunohistochemistry of myocardial tissue sections at week 6, in nicotine treated
group, reveals double staining against human specific CD31 and GFP antibody, indicating that
DF+hESC-ECs took part in the formation of vessel-like
structures.
doi:10.1371/journal.pone.0007040.g004
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presence of 10
28 M nicotine in hypoxic conditions (Figure S1).
Furthermore, to preclude the possibility that nicotine and/or
hypoxia may impart pro-survival cues by modulating nAChR gene
expression, we showed by real-time PCR analysis that neither
nicotine nor hypoxia significantly affected the gene expression of
Figure 5. Effect of
DF+hESC-ECs transplantation and nicotine administration on neovascularization in the peri-infarct area. (A)
Immunohistochemistry using mouse specific CD31 (brown color) was performed on tissue sections from animals receiving intramyocardial injections
of
DF+hESC-EC or vehicle, in the presence or absence of nicotine treatment. (B) Quantification data showed
DF+hESC-EC transplantation plus 2 week
nicotine administration group had the highest vessel density, compared with PBS + vehicle, PBS + nicotine, and
DF+hESC-EC + vehicle groups
(*P,0.01) Scale bar, 50 mm.
doi:10.1371/journal.pone.0007040.g005
Figure 6. Nicotine’s effects on hESC-EC apoptosis and angiogenesis in response to hypoxia in vitro. (A–B) hESC-ECs were seeded on GFR
Matrigel-coated plate and incubated in a hypoxic condition (1% O2) with different concentrations of nicotine. 10
28 M nicotine resulted in significantly
more tube-formation compared to other groups (n=8, *P,0.05, ***P,0.001). (C–D) hESC-ECs were treated with 10
28 M nicotine or vehicle in
hypoxic conditions. Flow cytometry analysis was then used to assess cell staining for 7-AAD (dead cell marker) and Annexin-V (apoptosis marker) after
24 and 48 hours. 10
28 M nicotine significantly attenuated the percentage of dead and apoptotic hESC-ECs at 24 and 48 hours (n=8). (E) Western
analysis revealed that hypoxia (for 48 hrs) reduced, and nicotine (10
28 M) restored, pMAPK expression. Hypoxia increased pAkt, as did nicotine to a
greater extent. (F–I) Quantitative PCR revealed that nicotine further increased the expression of an upregulation of VEGF-A and bFGF, an effect that
was abrogated by the nAChR antagonist bungarotoxin (Bun). Expression of FLT-1 and FLK-1 was unchanged by nicotine. Scale bar, 20 mm.
doi:10.1371/journal.pone.0007040.g006
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results show that the activation of nAChRs led to an anti-apoptotic
effect and a pro-angiogenic effect of 10
28 M nicotine on hESC-
ECs in hypoxic conditions.
To further investigate the mechanism governing the pro-
survival effects of nicotine in hypoxia, we tested the effect of
10
28 M nicotine on the expression of MAPK, phosphorylated
MAPK (pMAPK), Akt, phosphorylated Akt (pAkt), and hypoxia
inducible factor-1 alpha (HIF-1a), all of which are involved in cell
proliferation, survival, apoptosis, and angiogenesis (Figure 6E,
Figure S3). The expression levels of both MAPK and Akt
remained unchanged by nicotine in all treatment groups.
However, after 48-hour exposure of the cells to hypoxia,
10
28 M nicotine enhanced the phosphorylation of MAPK. In
both normoxic and hypoxic conditions, 10
28 M nicotine induced
the phosphorylation of Akt, suggesting an effect of nAChR
activation on these signaling molecules. HIF-1a was upregulated
in hypoxia but showed non-significant trends of increased
activation in the presence of nicotine. In addition to protein
expression, quantitative PCR analysis revealed that nAChR
activation during hypoxia could selectively up-regulate the
angiogenic genes bFGF and VEGF-A, but not FLT1 or FLK1
expression (Figure 6F–I, Table S1). This effect was blocked by
the nAChR antagonist, a-bungarotoxin (a-BTX). These results
suggest that nAChR activation in the presence of hypoxia could
promote the up-regulation of VEGF and bFGF gene expression,
and that MAPK and Akt phosphorylation is likely to be involved
in nAChR-mediated effects on hESC-ECs.
To verify the role of Akt in modulating nicotine’s enhancement
in cell survival under hypoxic conditions, hESC-ECs were cultured
in EBM in 1% O2 hypoxia in the presence or absence of 10
28 M
nicotine for 24 h before being treated by 5 mM Akt IV inhibitor.
As shown in Figure S4, the Akt IV inhibitor stimulated increased
cell death when compared to the control group, and this effect was
partially blunted by the co-administration of both Akt IV inhibitor
and nicotine. This data suggests that inhibiting the Akt pathway
led to increased cell death, and this effect could be partially
reversed by nicotine. This finding concurs with our immunoblot-
ting data by demonstrating the importance of Akt and nAChR
activation for cell survival during hypoxia.
Discussion
The ability to obtain a potentially unlimited source of
endothelial cells from hESCs holds great promise for future
regenerative medicine therapies. However, stem cell therapy for
cardiovascular disease will ultimately be used in patients with risk
factors such as tobacco smoking. We therefore were interested
whether nicotine, a key component of tobacco smoke, would have
any effect on the survival or incorporation of hESC-ECs into the
ischemic heart. Surprisingly, short-term exposure to nicotine at
clinically relevant concentrations (eg. in the nanomolar range)
enhanced hESC-EC survival in the ischemic heart, and new vessel
formation. Following intramyocardial injection of
DF+hESC-ECs,
we observed a rapid decrease in imaging intensity over seven days
in the control group, which indicated significant cell death.
However, we were surprised to see significant prolongation of
DF+hESC-EC survival in the nicotine-treated group out to 5 weeks.
To understand the mechanism of nicotine-induced hESC-EC
survival, we next performed a series of in vitro experiments using
different concentrations of nicotine (10
28 Mt o1 0
22 M). Signif-
icant cell death occurred at the higher concentrations (10
24–
10
22 M), but at lower concentrations (10
28–10
26 M) we observed
increased proliferation, anti-apoptosis, and angiogenesis. In
particular, the 10
28 M concentration had the largest effect on
proliferation. Our in vitro analysis suggests that as a non-selective
agonist of nAChRs, nicotine (at the clinically relevant dose of
10
28 M) can improve hESC-EC angiogenesis and prevent
apoptosis under hypoxia through MAPK and Akt signaling
pathways. Furthermore, nAChR activation led to upregulation
of VEGF-A and bFGF gene expression and enhanced hESC-EC
survival and neovasculature formation after delivery in ischemic
heart tissue. Interestingly, the finding that angiogenesis was
upregulated after hESC-EC transplantation followed by low-dose
nicotine administration suggests that the activation of nAChRs can
improve the paracrine effect of hESC-EC on VEGF secretion,
which is another benefit from stem cell therapy[30].
One limitation of this study is that
DF+hESC-ECs were used for
in vivo studies, whereas non-transduced cells were assessed for cell
survival and angiogenic effects. However, we have shown that the
DF+hESC-ECs cells exhibit similar proliferation, viability, and
phenotypic markers as non-transduced cells (Figure 3C–D,
Figure 4C). This result is in agreement with our previous reports
that show that transduced hESCs maintain the pluripotent stem
cell phenotype. Therefore, it is likely that both
DF+hESC-ECs and
non-transduced hESC-ECs respond to nAChR activation in a
similar manner.
Our investigation into nicotine’s effects on stem cell survival is
only the latest study of this drug after decades of research into its
cellular and physiologic effects. In recent years, a growing body of
evidence indicates that non-neuronal nAChRs, when activated by
nicotine, may play a prominent role in endothelial cell survival,
proliferation[31], and mobilization[32], through their angiogen-
ic[25,33,34], anti-inflammatory[35,36], and anti-apoptotic[37,38]
properties. Along with acetylcholine, nicotine is a ligand for
nAChRs, which are cholinergic ion channels found in plasma
membranes of many different cell types, primarily neurons.
Evidence suggests that non-neuronal nAChRs are involved in
the regulation of vital cell functions, such as mitosis, differentia-
tion, organization of the cytoskeleton, cell-cell contact, locomo-
tion, and migration [22,25,31,34,37]. Furthermore, at clinically
relevant concentrations of nicotine (i.e., 1-100 nM range experi-
enced by smokers or individuals treated with nicotine), nicotine
has been shown to promote angiogenesis in a number of in vivo
settings, including inflammation, wound healing, ischemia, tumor,
and atherosclerosis[22,25,33,34].
However, these unexpected effects of nicotine, along with their
implications for cell-based therapies, are often countered by other
compounds found in tobacco smoke. Though nicotine is a key
addictive component of tobacco, it is notable that tobacco smoke
consists of more than 4,000 chemicals[39], many of them
carcinogenic or otherwise toxic. For example, the liquid vapor
portion of the smoke aerosol contains the compounds acrolein[40]
and benzopyrene[41], which are known to be cytotoxic and
mutagenic, and may account for some of second-hand smoke’s
toxicities[42]. Nicotine is thus not the sole or even most important
mediator of tobacco’s harmful effects, and studies demonstrating
its angiogenic and proliferative properties through nAChRs on
endothelial cells have hinted at the intriguing and varied bio-
activities of this compound.
In summary, this is the first study to investigate the effect of
nAChRs on hESC-EC behavior both in vitro and in vivo, as well as
the first study to elucidate the relationship between nAChRs
activation and the downstream signaling pathways including
MAPK, Akt, and HIF-1a. MAPK cascades are well known multi-
functional signaling networks that influence cell growth, differen-
tiation, apoptosis, and cellular responses to stress. HIF-1a is an
important transcriptional factor that activates the gene expression
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which confer hypoxic tolerance through angiogenesis, erythro-
poeisis, vasodilation, and altered glucose metabolism. We have
demonstrated in vitro that the activation of nAChRs by its ligand—
a low dose of nicotine—can trigger anti-apoptotic, angiogenic, and
proliferative pathway. Furthermore, systemic in vivo administra-
tions of nicotine protected hESC-ECs from acute cell loss after
transplantation to ischemic heart tissue. Taken together, we
believe the activation of nAchRs has a potential positive role to
play in regenerative medicine, and may become valuable for
improving hESC-EC survival and, ultimately, therapeutic efficacy.
Supporting Information
Figure S1 Effect of nicotine on cell proliferation in hypoxia in
vitro. hESC-ECs were cultured in 1% O2 in the presence of PBS or
10
28 M nicotine for up to 2 days. (A) Cell proliferation was
assayed by BrdU incorporation (green) and expressed as a
percentage of total cell nuclei (blue). (B) Quantification of BrdU+
cells after 1 and 2 days. Data is shown as mean 6 standard
deviation (n=3). Scale bar, 50 mm.
Found at: doi:10.1371/journal.pone.0007040.s001 (3.18 MB TIF)
Figure S2 Effects of nicotine or hypoxia on the expression of
nAChR subunits in hESC-ECs. Taqman real-time PCR showed
no significant effect of 48-hour hypoxia or 10
28 M nicotine on a1,
a5, a7 and a9 nAChR expression. Data is normalized to 18S
housekeeping gene and expressed as fold changes 6 standard
deviation, relative to the normoxia treatment group (n=3).
Found at: doi:10.1371/journal.pone.0007040.s002 (3.18 MB TIF)
Figure S3 Effect of nicotine on the activation of signaling
pathways. Quantification of immunoblots for (A) pMAPK,, (B)
pAkt, and (C) HIF1a. Data for pMAPK and pAkt were
normalized to total MAPK or Akt, respectively. HIF1a abundance
was normalized to total actin. Data is shown as mean 6 standard
error of mean (n=3).
Found at: doi:10.1371/journal.pone.0007040.s003 (3.18 MB TIF)
Figure S4 Role of nicotine in Akt-mediated improvement of cell
viability in hypoxia. After 24 h in the presence of hypoxia and
nicotine, cells were incubated with 5 mM Akt IV inhibitor,
10
28 M nicotine, or Akt IV inhibitor + Nicotine for 1 h before
assaying for cell viability (n=4). Scale bar, 200 mm.
Found at: doi:10.1371/journal.pone.0007040.s004 (3.18 MB TIF)
Table S1 Effect of nicotine on angiogenic genes expression. The
downstream gene expression of both VEGF-A and bFGF were up-
regulated, but FLT-1 and FLK-1 expression remained unchanged.
Data is normalized to 18S housekeeping gene and expressed as
fold changes 6 standard deviation, relative to the normoxia
treatment group (n=4).
Found at: doi:10.1371/journal.pone.0007040.s005 (3.18 MB TIF)
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